seqWell
seqWell, founded in 2014 and based in Beverly, Massachusetts, develops proprietary TnX transposase-based NGS library preparation kits sold to genomics labs across pharma, biotech, academia, and agricultural biotechnology in more than 20 countries.
- Company typePrivate
- Founded2014
- HeadquartersBeverly, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What seqWell does
seqWell, Inc. is a privately held life sciences tools company founded in February 2014 by Joe Mellor and Jack Leonard, headquartered at 66 Cherry Hill Drive in Beverly, Massachusetts. The company develops and sells a portfolio of next-generation sequencing (NGS) library preparation kits and reagents used by genomics laboratories in pharmaceutical and biotechnology firms, academic and clinical research institutions, agricultural biotechnology organizations, and genomics service providers. Products include the ExpressPlex 2.0, MosaiX, LongPlex, AgriPrep, and upcoming ExpressPlex Plus kits, supported by the Tagify family of custom-loaded transposases and the PhiRx indexed control. The portfolio is sold directly in the United States and through a network of regional distributors covering more than 20 countries across North America, Europe, the Middle East, Asia Pacific, and Latin America.
The company's core technological asset is TnX, a next-generation transposase developed through more than 20 cycles of directed evolution to improve on the widely used Tn5 enzyme in activity, insertion-site bias, and robustness. TnX powers seqWell's tagmentation-based workflows, including the proprietary ExpressPlex one-step fragmentation-tagging-amplification method and a directional tagmentation chemistry used in the MosaiX kit. These workflows deliver quantified throughput and cost advantages — 100-minute library prep with 30 minutes hands-on time, up to 6,144-plex multiplexing, 95% consumables reduction, and 80% reduction in required sequencing depth through built-in auto-normalization — and are compatible with Illumina, PacBio, Element Biosciences, Complete Genomics, and Ultima Genomics sequencing platforms. Tagify loaded transposases extend the chemistry into gene editing QC and targeted sequencing applications such as GUIDE-seq2, UDiTaS, and ATAC-Seq.
seqWell generates revenue through one-time sales of kits and reagents with recurring purchasing from established customers; pricing is not publicly disclosed and is provided on a request-for-quote basis. Go-to-market combines US enterprise field sales with global distributor partnerships and a content-led marketing program including webinars, peer-reviewed publications, and participation in AGBT, PAG, and ASHG. The company is ISO 9001:2015 certified, holds a filed patent on its core NGS library prep technology, and has raised approximately $33 million in cumulative funding, including a $7 million Series C led by Codexis in April 2022 that included a strategic enzyme-engineering collaboration.
seqWell firmographics
Firmographics- Name
- seqWell
- Legal name
- seqWell, Inc.
- Website
- https://seqwell.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- seqWell, founded in 2014 and based in Beverly, Massachusetts, develops proprietary TnX transposase-based NGS library preparation kits sold to genomics labs across pharma, biotech, academia, and agricultural biotechnology in more than 20 countries.
- Ownership category
- akta.pro rank
seqWell industry classification
Industry- Product category
- Genomics Reagents and NGS Library Preparation
- NAICS
- Medical and Diagnostic Laboratories (6215), Computer Systems Design and Related Services (54151)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)
- akta.pro secondary industry
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where seqWell is headquartered
LocationHeadquarters
- HQ city
- Beverly
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
seqWell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- NGS Library Preparation Kits and Reagents: seqWell generates revenue through the sale of library preparation kits, transposase reagents, and multiplexing solutions for next-generation sequencing applications. Products include AgriPrep, ExpressPlex 2.0, ExpressPlex Plus, LongPlex, MosaiX, and Tagify loaded transposases sold in various formats (96-well, 384-well, bulk reagents). Revenue is one-time product sales with recurring purchasing from established customers.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
seqWell product offering
Product offeringCore offering
seqWell develops and sells proprietary NGS (next-generation sequencing) library preparation kits, transposase reagents, and multiplexing solutions powered by its engineered TnX transposase. Its portfolio enables simplified one-step tagmentation workflows for high-throughput genomics applications including plasmid/amplicon sequencing, microbial WGS, low-pass WGS for agrigenomics, gene editing QC, and long-read sequencing compatible with Illumina, PacBio, Element, Complete Genomics, and Ultima platforms.
Product overview
seqWell offers a portfolio of multiplexed NGS library preparation kits based on proprietary TnX transposase technology. The core products include: AgriPrep for plant, animal, and human low-pass WGS; ExpressPlex 2.0 for plasmid and amplicon sequencing; ExpressPlex Plus for microbial WGS and metagenomics; LongPlex for PacBio long-read sequencing; and MosaiX for high-performance human WGS/WES. Supporting reagents include Tagify Custom-loaded Transposases (Tn5/TnX), Tagify i5 UMI Adapter-loaded Transposase, Tagify TnX Universal Adapters, and PhiRx Indexed Control. All products are powered by TnX transposase chemistry, which enables simplified tagmentation workflows with auto-normalization and massive multiplexing capabilities for scalable sequencing.
Differentiator
Problem solved
Functional benefit
Brands
- AgriPrep: Library preparation kit for plant, animal, and human low-pass WGS and SKIM-sequencing, powered by ExpressPlex workflow.
- ExpressPlex
- ExpressPlex Plus
- LongPlex
- MosaiX
- Tagify
- PhiRx
- TnX
Products and services
- AgriPrep Library Prep Kit One-step library preparation kit for plant, animal, and human low-pass WGS and SKIM-sequencing. Uses ExpressPlex workflow with auto-normalization, 100-minute protocol, 30 minutes hands-on time, and multiplexing up to 3,072 samples. Targets agrigenomics breeding programs and population-scale genotyping.
- MosaiX Library Prep Kit High-performance DNA library prep kit using directional tagmentation powered by proprietary TnX transposase. Produces high-complexity libraries with uniform coverage and low duplication rates for human WGS/WES and plant/animal genomics. 90-minute workflow with 35 minutes hands-on time.
- ExpressPlex 2.0 Library Prep Kit One-step library preparation kit powered by TnX transposase for high-throughput plasmid and amplicon sequencing. Auto-normalization, reduced insertion bias, improved coverage uniformity, and multiplexing up to 6,144 samples. Designed to replace multi-day workflows with a 65% faster process and >90% labor and consumables savings.
- ExpressPlex Plus Library Prep Kit Upcoming one-step library prep kit for high-throughput microbial WGS and metagenomics applications. ExpressPlex workflow with 100-minute protocol, auto-normalization, and up to 1,536 index combinations. Achieves uniform coverage across diverse GC-content microbial genomes. Marketed as 'Coming Soon' on seqwell.com.
- LongPlex Multiplexing Kit Plate-based enzymatic fragmentation and multiplexing kit for PacBio long-read HiFi sequencing. Eliminates mechanical shearing, simultaneously fragments and indexes up to 96 gDNA samples, producing 8-10 kb fragments. Compatible with PacBio Revio and Sequel II/IIe systems.
- Tagify Custom-loaded Transposase Custom-loaded transposase reagents (Tn5 or TnX) pre-loaded with customer-specified oligos including Illumina barcodes, universal adapters, UMIs, or custom sequences. For gene editing QC and targeted sequencing assays including GUIDE-seq2, UDiTaS, CHANGE-seq, and ATAC-Seq. Customers include Editas Medicine and Bristol Myers Squibb.
- Tagify i5 UMI Adapter-loaded Transposase Ready-to-use transposase pre-loaded with Illumina-compatible P5 + i5 + UMI + R1 adapter for CRISPR and gene editing QC. Includes 10-bp i5 barcode and 10-bp UMI, available in sets of 24 unique indexes. Supports GUIDE-seq2 off-target analysis.
- Tagify TnX Universal Adapters TnX transposase pre-loaded with Illumina-compatible universal adapters (P5 and P7) for rapid tagmentation-based library prep. Produces 650-850 bp fragments. Used for ATAC-Seq and other NGS assays requiring Illumina-compatible sequence adapters.
- PhiRx Indexed Control Dual-indexed control library derived from phiX174 genomic DNA optimized for Illumina XLEAP SBS chemistry sequencing platforms. Provides color-balancing spike-in control to improve demultiplexing and reduce undetermined reads from 53% to <2%. For NextSeq 1000/2000, NovaSeq X, and 10x Genomics runs.
Quantifiable outcome
- Up to 95% reduction in consumables compared to traditional library prep methods
- +6 more outcomes
Companies that use seqWell
Customer profileNamed customers18 records
Segments6 records
Ideal customer profiles3 records
seqWell technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration7 records
Feature5 records
seqWell partnerships and signals
Strategic signalScale indicators9 records
Recent moves6 records
Expansion highlights7 records
seqWell competitors and assessment
Company assessmentMarket position
Strengths2 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
seqWell social profiles
Digital presenceseqWell compliance and trust
Trust signalCompliance1 record
seqWell financial estimates
Financial estimateRevenue estimate
Valuation estimate
seqWell leadership team
Management profileNumber of profiles
Profiles18 records
seqWell funding detail
Funding detailFunding overview
Funding rounds7 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
seqWell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about seqWell
What does seqWell do?
seqWell develops and sells proprietary NGS (next-generation sequencing) library preparation kits, transposase reagents, and multiplexing solutions powered by its engineered TnX transposase. Its portfolio enables simplified one-step tagmentation workflows for high-throughput genomics applications including plasmid/amplicon sequencing, microbial WGS, low-pass WGS for agrigenomics, gene editing QC, and long-read sequencing compatible with Illumina, PacBio, Element, Complete Genomics, and Ultima platforms.
Is seqWell a public or private company?
seqWell is a private company. It is classified as venture growth investor backed and is currently operating.
When was seqWell founded?
seqWell was founded in 2014. It employs 1 to 10 people.
Where is seqWell based?
seqWell is headquartered in Beverly, United States, in the North America region.
How does seqWell make money?
One revenue line is on record: NGS Library Preparation Kits and Reagents.
Does seqWell have an API?
No public API is recorded for seqWell.
What industry is seqWell in?
seqWell's product category is Genomics Reagents and NGS Library Preparation. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays). Its NAICS code is 6215 and its SIC code is 8071.